Historical dhr News Stories
Danaher Tops Q4; Diagnostics & Precision Push Now!
Danaher reported stronger-than-expected Q4 results, raised 2026 guidance range, and showed tangible momentum in diagnostics—driven by new-product launches, a stabilization in China, and a strategic tie-up with AstraZeneca—positioning DHR for durable growth across life-science instruments and molecular diagnostics.
Danaher Q4: Biotech Lifts Growth, Margins Slip Now
Danaher reported Q4 strength in biotechnology but saw operating margins compress across segments. Revenue beat and EPS exceeded expectations, yet investors focused on margin pressure and cautious 2026 guidance—driving early-February share volatility.